Monday, September 8, 2008

Basilea's Toctino (alitretinoin) Receives First National Marketing Authorization in the UK

September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

The details can be read here.

No comments: